Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Wednesday, Johnson & Johnson (NYSE:JNJ) reported a second-quarter adjusted EPS of $2.82, up 10.2% Y/Y, beating the consensus of $2.70.
週三，強生公司（紐約證券交易所代碼：JNJ）公佈的第二季度調整後每股收益爲2.82美元，同比增長10.2％，超過市場預期的2.70美元。
RBC Capital Markets anticipates a favorable second-quarter environment for companies outside of China. They expect the third quarter to follow typical seasonal patterns without backlog issues, with robust MedTech markets projected for 2024 and beyond.
加拿大皇家銀行資本市場預計，中國以外的公司將迎來有利的第二季度環境。他們預計，第三季度將遵循典型的季節性模式，不會出現積壓問題，預計2024年及以後的醫療技術市場將保持強勁。
Johnson & Johnson maintains its consistent M&A strategy, affirming continuity even after acquiring Shockwave Medical. The company asserts confidence in its ability to explore diverse opportunities moving forward.
強生公司保持其一貫的併購戰略，即使在收購Shockwave Medical之後，也確認了連續性。該公司對自己探索未來各種機會的能力充滿信心。
Johnson & Johnson has stated that while it is open to opportunities across all sectors and sizes, it prefers areas with existing expertise and capabilities.
強生公司表示，儘管它對所有行業和規模的機會持開放態度，但它更喜歡具有現有專業知識和能力的領域。
It emphasized its long-term approach to mergers and acquisitions, prioritizing sustainable growth over short-term gains.
它強調了其長期的併購方針，將可持續增長置於短期收益之上。
The RBC analyst adds that in the second quarter, both businesses showed sequentially increasing growth on a stacked 2-year basis, indicating improved fundamentals compared to the first quarter.
加拿大皇家銀行分析師補充說，在第二季度，兩項業務均連續2年增長，這表明基本面與第一季度相比有所改善。
Johnson & Johnson anticipates faster sales growth in its Medical Technology sector in the second half of 2024. However, it foresees a slowdown in sales growth for Innovative Medicine, mainly due to the entry of a biosimilar for Stelara in Europe.
強生公司預計，其醫療技術領域的銷售增長將在2024年下半年加快。但是，它預計創新醫學的銷售增長將放緩，這主要是由於Stelara的生物仿製藥進入歐洲。
RBC Capital maintains the Outperform rating with a price target of $175.
加拿大皇家銀行資本維持跑贏大盤評級，目標股價爲175美元。
Truist Securities says the management noted Imbruvica continues to experience competitive pressure, including Jaypirca, which was developed by Eli Lilly And Co (NYSE:LLY).
Truist Securities表示，管理層指出，Imbruvica繼續面臨競爭壓力，其中包括由禮來公司（紐約證券交易所代碼：LLY）開發的Jaypirca。
"In our view, this may reflect physician demand for novel options that can address resistance to older and less efficacious molecules such as Imbruvica," Truist analyst writes.
Truist分析師寫道：“在我們看來，這可能反映了醫生對新選擇的需求，這些新選擇可以解決對Imbruvica等較舊、效果較差的分子的耐藥性。”
Johnson & Johnson reports strong Tecvayli demand despite slower growth following FDA approval for a longer dosing interval. Pfizer Inc's (NYSE:PFE) Elrexfio allows biweekly dosing after week 24, contrasting with Tecvayli's weekly dosing regimen.
強生公司報告稱，在美國食品藥品管理局批准延長給藥間隔後，儘管增長放緩，但Tecvayli的需求仍強勁。輝瑞公司（紐約證券交易所代碼：PFE）的Elrexfio允許在第24周之後每兩週給藥一次，這與Tecvayli的每週給藥方案形成鮮明對比。
This suggests a potential positive signal for Elrexfio. Meanwhile, attention is on Regeneron Pharmaceutical Inc's (NASDAQ:REGN) linvoseltamab, anticipated to offer a best-in-class profile with promising response rates (71% ORR and 46% CR or better).
這表明Elrexfio可能出現積極信號。同時，Regeneron Pharmaceutical Inc（納斯達克股票代碼：REGN）的linvoseltamab備受關注，該公司預計將提供一流的概況，回覆率令人鼓舞（ORR爲71％，CR爲46％或更高）。
Price Action: JNJ Stock is down 0.42% at $155.92 at last check Thursday.
價格走勢：在週四的最後一次檢查中，JNJ股票下跌0.42％，至155.92美元。
Photo via Shutterstock
照片來自 Shutterstock